Académique Documents
Professionnel Documents
Culture Documents
Jeffrey M. Smith Sheena Currie Tirza Cannon Julia Perri 6 May 2012
Methodology
41 Countries January March 2012 National level Self reporting of national stakeholder group Data collection
44 item questionnaire Scale up maps: PPH & PE/E English, French, Spanish
2011 and 2012 questionnaires same except for few questions. Results comparable but more precise.
Results
Responses from 37 countries:
All responses complete
7 new countries included:
Cambodia, East Timor, Ecuador, El Salvador, Pakistan, Philippines, Yemen
Presentation of Results
Findings in 8 themes 1A: Availability of medicines: Uterotonics 1B: Availability of medicines for PE/E MgSO4 and antihypertensives 2: Medicines approved at national level 3: AMTSL 4: Misoprostol 5: Midwife/SBA scope of practice 6: Education / Training in PPH and PE/E 7: Monitoring and evaluation 8: Scale up and bottlenecks
6
Presentation of Results
Findings in 8 themes
Global status of 2012 Comparisons of questions between 2011 and
2012
Oxytocin regularly available in facilities
0% 11%
26%
35% 74%
54%
n = 37
2012
19% 38% 8%
35%
n = 37
2011
Misoprostol on the EML for prevention of PPH
2012
Misoprostol on the EML for prevention of PPH
39% 61%
43%
57%
n = 31
Yes No Yes No
n = 37
2012 no yes no
2012
MgS04 regularly available in facilities
0%
24% 48%
52%
49%
27%
2012
Yes No
n = 31
n = 37
17
Preventing PPH with misoprostol: Program piloting and scale up, 2012 data, n = 37
18
19
Mixed Progress
Increased availability of oxytocin
2011: 74% of countries (23 of 31) 2012: 89% of countries (33 of 37)
Mixed picture of misoprostol on national EML Recall that in 2011 misoprostol added to WHO EML
2011: 61% of countries (19 of 31)
Conclusions
Some drugs are more available We lack coverage data for use of these drugs Variety in approval of different antihypertensives Mixed picture of misoprostol on national EML Some movement in initial programs on use of misoprostol PPH Programs more robust than PE/E Programs
21
Thank you
22
wwww.mchip.net
Follow us on: